Fifth Liverpool Tropical School Bayer Symposium on Microbial Diseases, 14 February 1998: Tropical and exotic infections

Journal of Medical Microbiology

Volumn 49, Issue 1, 2000, Pages 5-27

  Beeching, N J ^a   Hart, C A ^b   Duerden, B I ^c  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHOLERA VACCINE; PLAGUE VACCINE;

ANTIBIOTIC RESISTANCE; CHOLERA; EHRLICHIOSIS; EPIDEMIC; HUMAN; MELIOIDOSIS; MULTIDRUG RESISTANCE; PATHOGENESIS; PLAGUE; PRIORITY JOURNAL; REVIEW; TROPICAL MEDICINE; TYPHOID FEVER; YERSINIA PESTIS; COMMUNICABLE DISEASE; CONFERENCE PAPER; DRUG EFFECT; MICROBIOLOGY; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SALMONELLOSIS;

CHOLERA; COMMUNICABLE DISEASES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; EHRLICHIOSIS; HUMANS; MELIOIDOSIS; PARATYPHOID FEVER; PLAGUE; SALMONELLA PARATYPHI A; SALMONELLA TYPHI; TROPICAL MEDICINE; TYPHOID FEVER;

EID: 0033630358     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-49-1-5     Document Type: Review

References (245)

1. Power HJ. Tropical medicine in the twentieth century: A history of the Liverpool School of Tropical Medicine, 1898-1990. London, Kegan Paul International. 1999.
2. Miller PJ. Malaria, Liverpool: An illustrated history of the Liverpool School of Tropical Medicine 1898-1998. Liverpool, Liverpool School of Tropical Medicine. 1998.
3. Frazer WM. Duncan of Liverpool: being the work of Dr WH Duncan, Medical Officer of Health, 1847-63. Preston, Carnegie. 1997.
4. Cox FEG (ed). Wellcome Trust illustrated history of tropical diseases. London, Wellcome Trust. 1996.
5. Wilkinson L, Hardy A. The London School of Hygiene and Public Health: a twentieth century quest for global public health. London, Kegan Paul International. 1998.
6. Human plague in 1994. Wkly Epidemiol Rec 1996; 71: 165-168.
7. Wilmoth BA, Chu MC, Quan TJ. Identification of Yersinia pestis by BBL Crystal Enteric/Nonfermenter Identification System. J Clin Microbiol 1996; 34: 2829-2830.
8. Friedlander AM, Welkos SL, Worsham PL et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis 1995; 21 Suppl 2: S178-S181.
9. Guiyoule A, Grimont F, Iteman I, Grimont PAD, Lefèvre M, Carniel E. Plague pandemics investigated by ribotyping of Yersinia pestis strains. J Clin Microbiol 1994; 32: 634-641.
10. Christie AB. Infectious diseases epidemiology and clinical practice, 4th edn. Edinburgh, Churchill Livingstone. 1987.
11. Maevskii MP, Bazanova LP, Konnov NP, Kapustin IUM, Sakharov SV. [The variability of Yersinia pestis in the body of the flea.] Zh Mikrobiol Epidemiol Immunobiol 1994; 3: 16-21.
12. Bray R S. Plague. In: Cox FEG (ed) Wellcome Trust illustrated history of tropical diseases. London, Wellcome Trust. 1996.
13. Doll JM, Zeitz PS, Ettestad P, Bucholtz AL, Davis T, Gage K. Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. J Trop Med Hyg 1994; 51: 109-114.
14. Christie AB, Chen TH, Elberg SS. Plague in camels and goats: their role in human epidemics. J Infect Dis 1980; 141: 724-726.
15. Legters LJ, Cottingham AJ, Hunter DH. Clinical and epidemiological notes on a defined outbreak of plague in Vietnam. Am J Trop Med Hyg 1970; 19: 639-652.
16. Anderson GW, Worsham PL, Bolt CR et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg 1997; 56: 471-473.
17. Fatal human plague - Arizona and Colorado, 1966. Morbid Mortal Wkly Rep 1997; 46: 617-620.
18. Hull HF, Montes JM, Mann JM. Septicemic plague in New Mexico. J Infect Dis 1987; 155: 113-118.
19. Franz DR, Jahrling PB, Friedlander AM et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.
20. McClean KL. An outbreak of plague in Northwestern Province, Zambia. Clin Infect Dis 1995; 21: 650-652.
21. Cao LK, Anderson GP, Ligler FS, Ezzell J. Detection of Yersinia pestis fraction 1 antigen with a fiber optic biosensor. J Clin Microbiol 1995; 33: 336-341.
22. Norkina OV, Kulichenko AN, Gintsburg AL et al. Development of a diagnostic test for Yersinia pestis by the polymerase chain reaction. J Appl Bacteriol 1994; 76: 240-245.
23. Kumar S. Confirmation of Indian plague outbreak? Lancet 1995; 345: 443.
24. Tsukano H, Itoh K, Suzuki S, Watanabe H. Detection and identification of Yersinia pestis by polymerase chain reaction (PCR) using multiplex primers. Microbiol Immunol 1996; 40: 773-775.
25. Butler T. Yersinia species (including plague). In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett's principles and practice of infectious diseases, 4th edn, vol 2. Edinburgh, Churchill Livingstone. 1995: 2070-2078.
26. Smith MD, Vinh DX, Hoa NTT, Wain J, Thung D, White NJ. In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrob Agents Chemother 1995; 39: 2153-2154.
27. Bonacorsi SP, Scavizzi MR, Guiyoule A, Amoroux JH, Carniel E. Assessment of a fluoroquinolone, three beta lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection. Antimicrob Agents Chemother 1994; 38: 481-486.
28. Galimand M, Guiyoule A, Gerbaud G et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997; 337: 677-680.
29. Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970; 42: 653-666.
30. Titball RW, Howells AM, Oyston PC, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 1997; 65: 1926-1930.
31. Anderson GW, Leary SEC, Williamson ED et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 1996; 64: 4580-4585.
32. Pullen JK, Anderson GW, Welkos SL, Friedlander AM. Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes. Infect Immun 1998; 66: 521-527.
33. Williamson ED, Eley SM, Griffin KF et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 1995; 12: 223-230.
34. Williamson ED, Sharp GJE, Eley SM et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 1996; 14: 1613-1619.
35. Whitmore A, Krishnaswami CS. An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. Ind Med Gazette 1912; 47: 262-267.
36. Dance DAB. Melioidosis: the tip of the iceberg? Clin Microbiol Rev 1991; 4: 52-60.
37. Dharakul T, Songsivilai S. Recent developments in the laboratory diagnosis of melioidosis. J Infect Dis Antimicrob Agents 1996; 13: 77-80.
38. Suputtamongkol Y, Hall AJ, Dance DAB et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol 1994; 23: 1082-1090.
39. Boonsawat W, Boonma P, Tangdajahiran T, Puapermpoonsiri S, Wongpratoom W, Romphryk A. Community-acquired pneumonia in adults at Srinagarind Hospital. J Med Assoc Thai 1990; 73: 345-351.
40. Anonymous. Melioidosis in Singapore. Epidemiologic News Bull (Singapore) 1995; 21: 69-72.
41. Yang S, Tong S, Lu Z. Geographical distribution of Pseudomonas pseudomallei in China. Southeast Asian J Trop Med Public Health 1995; 26: 636-638.
42. Lee SS-J, Liu Y-C, Chen Y-S et al. Melioidosis: two indigenous cases in Taiwan. J Formos Med Assoc 1996; 95: 562-566.
43. John JT, Jesudason MV, Lalitha MK et al. Melioidosis in India: the tip of the iceberg? Ind J Med Res 1996; 103: 62-65.
44. Currie B. Melioidosis and the monsoon in tropical Australia. Commun Dis Intell (Australia) 1996; 20: 63.
45. Van der Lugt JJ, Henton MM. Melioidosis in a goat. J S Afr Vet Assoc 1995; 66: 71-73.
46. Olive C, Loetitia G, Desbois N, Roche B, Jouannelle J, Dodin A. [Septic pyemic form of human melioidosis: a first case in the French Antilles.] Forme septico-pyohémique de mélioïdose humaine: un premier cas aux Antilles Françaises. Presse Med 1995; 24: 1270.
47. Pérez J-M, Petiot A, Adjidé C, Gerry F, Goursaud R, Juminer B. First case of melioidosis in Guadeloupe, a French West Indies Archipelago. Clin Infect Dis 1997; 25: 164-165.
48. Wuthiekanun V, Smith MD, Dance DAB, White NJ. Isolation of Pseudomonas pseudomallei from soil in north-eastern Thailand. Trans R Soc Trop Med Hyg 1995; 89: 41-43.
49. Smith MD, Wuthiekanun V, Walsh AL, White NJ. Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Trans R Soc Trop Med Hyg 1995; 89: 488-490.
50. Wuthiekanun V, Smith MD, Dance DAB, Walsh AL, Pitt TL, White NJ. Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei. J Med Microbiol 1996; 45: 408-412.
51. Trakulsomboon S, Dance DAB, Smith MD, White NJ, Pitt TL. Ribotype differences between clinical and environmental isolates of Burkholderia pseudomallei. J Med Microbiol 1997; 46: 565-570.
52. Smith MD, Angus BJ, Wuthiekanun V, White NJ. Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun 1997; 65: 4319-4321.
53. Lim MK, Tan EH, Soh CS, Chang TL. Burkholderia pseudomallei infection in the Singapore Armed Forces from 1987 to 1994 - an epidemiological review. Ann Acad Med Singapore 1997; 26: 13-17.
54. Woods DE, Jones AL, Hill PJ. Interaction of insulin with Pseudomonas pseudomallei. Infect Immun 1993; 61: 4045-4050.
55. Suputtamongkol Y, Kwiatkowski D, Dance DAB, Chaowagul W, White NJ. Tumor necrosis factor in septicemic melioidosis. J Infect Dis 1992; 165: 561-564.
56. Matsuura M, Kawahara K, Ezaki T, Nakano M. Biological activities of lipopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. FEMS Microbiol Lett 1996; 137: 79-83.
57. Mohamed R, Nathan S, Embi N, Razak N, Ismail G. Inhibition of macromolecular synthesis in cultured macrophages by Pseudomonas pseudomallei exotoxin. Microbiol Immunol 1989; 33: 811-820.
58. Haase A, Janzen J, Barrett S, Currie B. Toxin production by Burkholderia pseudomallei strains and correlation with severity of melioidosis. J Med Microbiol 1997; 46: 557-563.
59. Sexton MM, Jones AL, Chaowagul W, Woods DE. Purification and characterization of a protease from Pseudomonas pseudomallei. Can J Microbiol 1994; 40: 903-910.
60. Kanai K, Kondo E. Recent advances in biomedical sciences of Burkholderia pseudomallei (basonym. Pseudomonas pseudomallei). Jpn J Med Sci Biol 1994; 47: 1-45.
61. Vorachit M, Lam K, Jayanetra P, Costerton JW. Electron microscopy study of the mode of growth of Pseudomonas pseudomallei in vitro and in vivo. J Trop Med Hyg 1995; 98: 379-391.
62. Yang H, Kooi CD, Sokol PA. Ability of Pseudomonas pseudomallei malleobactin to acquire transferrin-bound, lactoferrin-bound, and cell-derived iron. Infect Immun 1993; 61: 656-662.
63. Jones AL, Beveridge TJ, Woods DE. Intracellular survival of Burkholderia pseudomallei. Infect Immun 1996; 64: 782-790.
64. Egan AM, Gordon DL. Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect Immun 1996; 64: 4952-4959.
65. Dance DAB. Melioidosis and glanders. In: Collier L, Balows A, Sussman M (eds) Topley & Wilson's microbiology and microbial infections, 9th edn, vol 3 - Hausler WJ, Sussmann M (eds) Bacterial infections. London, Arnold. 1998: 919-929.
66. Woods ML, Currie BJ, Howard DM et al. Neurological melioidosis: seven cases from the Northern Territory of Australia. Clin Infect Dis 1992; 15: 163-169.
67. Walsh AL, Smith MD, Wuthiekanun V et al. Immunofluorescence microscopy for the rapid diagnosis of melioidosis. J Clin Pathol 1994; 47: 377-379.
68. White NJ, Dance DAB, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2: 697-700.
69. Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992; 36: 158-162.
70. Suputtamongkol Y, Rajchanuwong A, Chaowagul W et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19: 846-853.
71. Desmarchelier PM, Dance DAB, Chaowagul W, Suputtamongkol Y, White NJ, Pitt TL. Relationships among Pseudomonas pseudomallei isolates from patients with recurrent melioidosis. J Clin Microbiol 1993; 31: 1592-1596.
72. Chaowagul W, Suputtamongkol Y, Dance DAB, Rajchanuvong A, Pattara-arechachai J, White NJ. Relapse in melioidosis: incidence and risk factors. J Infect Dis 1993; 168: 1181-1185.
73. Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DAB, White NJ. A prospective comparison of coamoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1995; 89: 546-549.
74. Smith MD, Wuthiekanun V, Walsh AL, White NJ. In-vitro activity of carbapenem antibiotics against β-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother 1996; 37: 611-615.
75. Chaowagul W, Suputtamongkol Y, Smith MD, White NJ. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hygiene 1997; 91: 599-601.
76. Brett PJ, Woods DE. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide - flagellin protein conjugates. Infect Immun 1996; 64: 2824-2828.
77. Dance DAB, King C, Aucken H, Knott CD, West PG, Pitt TL. An outbreak of melioidosis in imported primates in Britain. Vet Rec 1992; 130: 525-529.
78. Mollaret HH. L'affaire du jardin des plantes ou comment Ia mélioïdose fit son apparition en France. Med Mal Infect 1988; 18: 643-654.
79. Pollitzer R. Cholera. Geneva: World Health Organization. 1959.
80. Barua D. History of cholera. In: Barua D, Greenough WB (eds) Cholera. New York, Plenum Medical. 1992: 1-36.
81. Bart KJ, Huq Z, Khan M, Mosley WH. Seroepidemiologic studies during a simultaneous epidemic of infection with E1 Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis 1970; 121 Suppl: S17-S24.
82. De SN. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature 1959; 183: 1533-1534.
83. Fasano A, Baudry B, Pumplin DW et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 1991; 88: 5242-5246.
84. Trucksis M, Galen JE, Michalski J, Fasano A, Kaper JB. Accessory cholera enterotoxin (Ace), the third toxin of a Vibrio cholerae virulence cassette. Proc Natl Acad Sci USA 1993; 90: 5267-5271.
85. Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the toxR regulon arc essential for Vibrio cholerae pathogenesis in humans. J Exp Med 1988; 168: 1487-1492.
86. Miller VL, Mekalanos JJ. Synthesis of cholera toxin is positively regulated at the transcriptional level by toxR. Proc Natl Acad Sci USA 1984; 81: 3471-3475.
87. Mekalanos JJ. Environmental signals controlling expression of virulence determinants in bacteria. J Bacteriol 1992; 174: 1-7.
88. Colwell RR, Seidler R, Kaper J et al. Occurrence of Vibrio cholerae serotype O1 in Maryland and Louisiana estuaries. Appl Environ Microbiol 1981; 41: 555-558.
89. Huq A, Small EB, West PA, Huq MI, Rahman R, Colwell RR. Ecological relationships between Vibrio cholerae and planktonic crustacean copepods. Appl Environ Microbiol 1983; 45: 275-283.
90. Morris JG, Johnson JA, Rice EW et al. Vibrio cholerae O1 can assume a rugose survival form which resists chlorination, but retains virulence for humans. In: Abstracts of the Twenty-ninth Joint Conference on Cholera and Related Diarrhoeal Diseases. Bethesda, MD, NIH. 1993.
91. Rice EW, Johnson CJ, Clark RM et al. Chlorine and survival of 'rugose' Vibrio cholerae. Lancet 1992; 340: 740.
92. Glass RI, Svennerholm A-M, Khan MR, Huda S, Huq MI, Holmgren J. Sero-epidemiological studies of E1 Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 1985; 151: 236-242.
93. Stock RF. Cholera in Africa: diffusion of the disease 1970 1975 with particular emphasis on West Africa. African Environmental Special Report No. 3. London, International African Institute. 1976.
94. Cholera situation in the Americas. An update. Epidemiol Bull 1991; 12: 1-4.
95. Birmingham ME, Lee LA, Ndayimirije N et al. Epidemic cholera in Burundi: patterns of transmission in the Great Rift Valley Lake region. Lancet 1997; 349: 981-985.
96. Rics AA, Vugia DJ, Beingolea L et al. Cholera in Piura, Peru: a modern urban epidemic. J Infect Dis 1992; 166: 1429-1433.
97. Deb BC, Sircar BK, Sengupta P, De SP, Saha MR, Pal SCG. Intra-familial transmission of Vibrio cholerae biotype El-Tor in Calcutta slums. Indian J Med Res 1982; 76: 814-819.
98. Koo D, Aragon A, Moscoso V et al. Epidemic cholera in Guatemala, 1993: transmission of a newly introduced epidemic strain by street vendors. Epidemiol Infect 1996; 116: 121-126.
99. Shears P. Cholera. Ann Trop Med Parasitol 1994; 88: 109-122.
100. Cholera Working Group. International Centre for Diarrhoeal Disease Research, Bangladesh. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 1993; 342: 387-390.
101. Faruque SM, Ahmed KM, Abdul Alim ARM, Qadri F, Siddique AK, Albert MJ. Emergence of a new clone of toxigenic Vibrio cholerae O1 biotypc E1 Tor displacing V. cholerae O139 Bengal in Bangladesh. J Clin Microbiol 1997; 35: 624-630.
102. Levine MM, Pierce NF. Immunity and vaccine development. In: Barua D, Greenough WB (eds) Cholera. New York, Plenum Medical Book Co. 1992: 285-327.
103. Sengupta DK, Sengupta TK, Ghose AC. Major outer membrane proteins of Vibrio cholerae and their role in induction of protective immunity through inhibition of intestinal colonization. Infect Immun 1992; 60: 4848-4855.
104. Beeley JC, Gangarosa EJ. Field trials of cholera vaccine. In: Cholera and related diarrheas. 43rd Nobel Symposium, Stockholm, Sweden, 1978. Basel, Karger. 1980: 204-210.
105. Clemens JD, Sack DA, Harris JR et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 2: 124-127.
106. Trach DD, Clemens JD, Ke NT et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997; 349: 231-235.
107. Levine MM, Tacket CO. Recombinant live cholera vaccines. In: Wachsmuth IK, Blake PA, Olsvik O (eds) Vibrio cholerae and cholera: molecular to global perspectives. Washington, DC, American Society for Microbiology. 1994: 395-413.
108. Kenner JR, Coster TS, Taylor DN et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 1995; 172: 1126-1129.
109. Goma Epidemiology Group. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July 1994? Lancet 1995; 345: 339-344.
110. WHO Wkly Epidemiol Rec 1998; 73: 201-207.
111. WHO Wkly Epidemiol Rec 1998; 73: 30.
112. Preston NW. Cholera vaccines: lessons from Rwanda and elsewhere. Lancet 1997; 349: 957.
113. Walker DH, Dumler JS. Emergence of the ehrlichioses as human health problems. Emerg Infect Dis 1996; 2: 18-29.
114. Ogden NH, Woldehiwet Z, Hart CA. Granulocytic ehrlichioses: an emerging or re-discovered tick-borne disease? J Med Microbiol 1998; 47: 475-482.
115. Misno T, Kobayashi Y. Studies on infectious mononucleosis (glandular fever). I. Isolation of etiologic agent from blood, bone marrow and lymph nodes from a patient with infectious mononucleosis by using mice. Kyushu J Med Sci 1955; 6: 146-152.
116. Popov VL, Han VC, Chen S-M et al. Ultrastructural differentiation of the genogroups in the genus Ehlichia. J Med Microbiol 1998; 47: 235-251.
117. Jafari S, Gaur SNS, Hashimi A. Prevalence of Ehrlichia canis in dog population of Shiraz, Fars province of Iran. J Appl Anim Res 1997; 11: 19-23.
118. Baneth G, Waner T, Koplah A, Weinstein S, Keysary A. Survey of Ehrlichia canis antibodies among dogs in Israel. Vet Rec 1996; 138: 257-259.
119. Bauer J. Infection with Ehrlichia platys and Ehrlichia canis in a dog. Kleintier Praxis 1995; 40: 947-952.
120. Matthewman LA, Kelly PJ, Wray K et al. Antibodies in cat sera from southern Africa react with antigens of Ehrlichia canis. Vet Rec 1996; 138: 364-365.
121. Mathew JS, Ewing SA, Barker RW et al. Attempted transmission of Ehrlichia canis by Rhipicephalus sanguineus after passage in cell culture. Am J Vet Res 1996; 57: 1594-1598.
122. Harrus S, Waner T, Aizenberg I, Foley JE, Poland AM, Bark H. Amplification of ehrlichial DNA from dogs 34 months after infection with Ehrlichia canis. J Clin Microbiol 1998; 36: 73-76.
123. Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE. Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med 1987; 316: 853-856.
124. Fishbein DB, Sawyer LA, Holland CJ et al. Unexplained febrile illnesses after exposure to ticks: infection with an Ehrlichia? JAMA 1987; 257: 3100-3104.
125. Perez M, Rikihisa Y, Wen B. Ehrlichia canis-like agent isolated from a man in Venezuela: antigenic and genetic characterization. J Clin Microbiol 1996; 34: 2133-3139.
126. Dawson JE, Anderson BE, Fishbein DB et al. Isolation and characterization of an Ehrlichia sp from a patient diagnosed with human ehrlichiosis. J Clin Microbiol 1991; 29: 2741-2745.
127. Anderson BE, Dawson JE, Jones DC, Wilson KH. Ehrlichia chaffeensis: a new species associated with human ehrlichiosis. J Clin Microbiol 1991; 29: 2838-2842.
128. Sumner JW, Nicholson WL, Massung RF. PCR amplification and comparison of nucleotide sequences from the groESL heat shock operon of Ehrlichia species. J Clin Microbiol 1997; 35: 2087-2092.
129. Yu X, Walker DH. Sequence and characterization of an Ehrlichia chaffeensis gene encoding 314 amino acids highly homologous to the NAD A enzyme. FEMS Microbiol Lett 1997; 154: 53-58.
130. Dawson JE, Biggie KL, Warner CK et al. Polymerase chain reaction evidence of Ehrlichia chaffeensis, an etiologic agent of human ehrlichiosis, in dogs from south east Virginia. Am J Vet Res 1996; 57: 1175-1179.
131. Chen S-M, Dumler JS, Feng H-M, Walker DH. Identification of the antigenic constituents of Ehrlichia chaffeensis. Am J Trop Med Hyg 1994; 50: 52-58.
132. Paddock CD, Sumner JW, Shore GM et al. Isolation and characterization of Ehrlichia chaffeensis strains from patients with fatal ehrlichiosis. J Clin Microbiol 1997; 35: 2496-2502.
133. Yu X, Piesman JF, Olson JG, Walker DH. Geographic distribution of different genetic types of Ehrlichia chaffeensis. Am J Trop Med Hyg 1997; 56: 679-680.
134. Ohashi N, Zhi N, Zhang YL, Rikihisa Y. Immunodominant major outer membrane proteins of Ehrlichia chaffeensis are encoded by a polymorphic multigene family. Infect Immun 1998; 66: 132-139.
135. Lockhart JM, Davidson WR, Stallknecht DE, Dawson JE, Howerth EW. Isolation of Ehrlichia chaffeensis from wild white-tailed deer (Odocoileus virginianus) confirms their role as natural reservoir hosts. J Clin Microbiol 1997; 35: 1681-1686.
136. Telford SR, Dawson JE. Persistent infection of C3H/HeJ mice by Ehrlichia chaffeensis. Vet Microbiol 1996; 52: 103-112.
137. Morais JD, Dawson JE, Greene C, Filipe AR, Galhardas LC, Bacellar F. First European case of ehrlichiosis. Lancet 1991; 338: 633-634.
138. Pierard D, Levtchenko E, Dawson JE, Lauwers S. Ehrlichiosis in Belgium. Lancet 1995; 346: 1233-1234.
139. Uhaa IJ, Maclean JD, Greene CR, Fishbein DB. A case of human ehrlichiosis acquired in Mali: clinical and laboratory findings. Am J Trop Med Hyg 1992; 46: 161-164.
140. Jacobs JF, Schutze GE. Ehrlichiosis in children. J Pediatr 1997; 131: 184-192.
141. Fishbein DB, Kemp A, Dawson JE, Greene NR, Redus MA, Fields DH. Human ehrlichiosis: prospective active surveillance in febrile hospitalized patients. J Infect Dis 1989; 160: 803-809.
142. Standaert SM, Dawson JE, Schaffner W et al. Ehrlichiosis in a golf-orientated retirement community. N Engl J Med 1995; 333: 420-425.
143. Carter N, Miller NR. Fourth nerve palsy caused by Ehrlichia chaffeensis. J Neuro-ophthalmol 1997; 17: 47-50.
144. Barnewall RE, Rikihisa Y, Lee EH. Ehrlichia chaffeensis inclusions are early endosomes which selectively accumulate transferrin receptor. Infect Immun 1997; 65: 1455-1461.
145. Lee EH, Rikihisa Y. Absence of tumor necrosis factor alpha, interleukin-6 (IL-6) and granulocyte-macrophage colony-stimulating factor expression but presence of IL-1 beta, IL-8, and IL-10 expression in human monocytes exposed to viable or killed Ehrlichia chaffeensis. Infect Immun 1996; 64: 4211-4219.
146. Lee EH, Rikihisa Y. Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent pro-inflammatory cytokine mMRNA expression in human monocytes through sustained reduction of I kappa B-alpha and activation of NF-kappa B. Infect Immun 1997; 65: 2890-2897.
147. Breitschwerdt EB, Hegarty BC, Hancock SI. Doxycycline hyclate treatment of experimental canine ehrlichiosis followed by challenge inoculation with two Ehrlichia canis strains. Antimicrob Agents Chemother 1998; 42: 362-368.
148. Rikihisa Y, Zhi N, Wormser GP, Wen B, Horowitz HW, Hechemy KE. Ultrastructural and antigenic characterization of a granulocytic ehrlichiosis agent directly isolated and stably cultivated from a patient in New York State. J Infect Dis 1997; 175: 210-213.
149. Anderson BE, Greene CE, Jones DC, Dawson JE. Ehrlichia ewingii sp. nov., the etiologic agent of canine granulocytic ehrlichiosis. Int J Syst Bacteriol 1992; 42: 299-302.
150. Gravino AE, DeCaprariis D, Manna L, Cerundolo R, Sagazio P, Buonavoglia C. Preliminary report of infection in dogs related to Ehrlichia equi: description of three cases. New Microbiol 1997; 20: 361-363.
151. Magnarelli LA, Ijdo JW, Anderson JF, Madison JE, Dumler JS, Fikrig E. Antibodies to Ehrlichia equi in dogs from the northeastern United States. J Am Vet Med Assoc 1997; 211: 1134-1137.
152. Ewing SA, Dawson JE, Mathew JS, Barker RW, Pratt KW, Telford SR. Attempted transmission of human granulocytotropic Ehrlichia (HGE) by Amhlyomma americanum and Amblyomma maculatum. Vet Parasitol 1997; 70: 183-190.
153. Spencer RR, Parker RR. Rocky Mountain spotted fever: infectivity of fasting and recently fed ticks. Public Health Rep 1923; 38: 333-339.
154. Piesman J, Mather TN, Sinsky RJ, Spielman A. Duration of tick attachment and Borrelia burgdorferi transmission. J Clin Microbiol 1987; 25: 557-558.
155. Piesman J, Spielman A. Human babesiosis on Nantucket Island: prevalence of Babesia microti in ticks. Am J Trop Med Hyg 1980; 29: 742-746.
156. Katavolos P, Armstrong PM, Dawson JE, Telford SR. Duration of tick attachment required for transmission of granulocytic ehrlichiosis. J Infect Dis 1998; 177: 1422-1425.
157. Macleod J. Studies on tick-borne fever of sheep. II Experiments on transmission and distribution of the disease. Parasitology 1936; 28: 320-329.
158. Das S, Deponte K, Marcantonio NL et al. Granulocytic ehrlichiosis in tick-immune guinea pigs. Infect Immun 1998; 66: 1803-1805.
159. Wikel SK, Ramachandra RN, Bergman DK, Burkot TR, Piesman J. Infestation with pathogen-free nymphs of the tick Ixodes scapularis induces host resistance to transmission of Borrelia burgdorferi by ticks. Infect Immun 1997; 65: 335-338.
160. Barlough JE, Madigan JE, Kramer VL et al. Ehrlichia phagocytophila genogroup rickettsia in ixodid ticks from California collected in 1995 and 1996. J Clin Microbiol 1997; 35: 2018-2021.
161. Ogden NH, Brown K, Horrocks BK, Woldehiwet Z, Bennett M. Granulocytic ehrlichiae infection in ixodid ticks and mammals in woodlands and uplands of the United Kingdom. Med Vet Entomol 1998; 12: 423-429.
162. Cinco M, Padovan D, Murgia R et al. Coexistence of Ehrlichia phagocytophila and Borrelia burgdorferi sensu lato in Ixodes ricinus ticks from Italy as determined by 16S rRNA gene sequencing. J Clin Microbiol 1997; 35: 3365-3366.
163. Telford SR, Dawson JE, Katavolos P, Warner CK, Kolbert CP, Persing DH. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. Proc Natl Acad Sci USA 1996; 93: 6209-6214.
164. Belongia EA, Reed KD, Mitchell PD et al. Prevalence of granulocytic Ehrlichia infection among white-tailed deer in Wisconsin. J Clin Microbiol 1997; 35: 1465-1468.
165. Nicholson WL, Muir S, Sumner JW, Childs JE. Serologic evidence of infection with Ehrlichia spp. in wild rodents (Muridae: Sigmodontinae) in the United States. J Clin Microbiol 1998; 36: 695-700.
166. Pusterla N, Braun U, Wolfensberger C, Lutz H. Intrauterine infection with Ehrlichia phagocytophila in a cow. Vet Rec 1997; 141: 101-102.
167. Horowitz HW, Kilchevskey E, Haber S et al. Perinatal transmission of the agent of human granulocytic ehrlichiosis. N Engl J Med 1998; 339: 375-378.
168. Sumption KJ, Wright DJM, Cutler SJ, Dale BAS. Human ehrlichiosis in the UK. Lancet 1995; 346: 1487-1488.
169. Thomas DR, Sillis M, Coleman TJ et al. Low rates of ehrlichiosis and Lyme borreliosis in English farmworkers. Epidemiol Infect 1998; 121: 609-614.
170. Bakken JS, Krueth J, Tilden RS, Dumler JS, Kristiansen BE. Serological evidence of human granulocytic ehrlichiosis in Norway. Eur J Clin Microbiol Infect Dis 1996; 15: 829-832.
171. Lillini E, Macri G, Rombola P, Grazioloi D, Russinio F, Nuti M. Ehrlichia seropositivity in Italian foresters. Rickettsiae and Rickettsial diseases. Proceedings of the Vth International Symposium. Bratislava, Slovak Academy of Sciences. 1996.
172. Brouqui P, Dumler JS, Lienhand R, Brossard M, Raoult D. Human granulocytic ehrlichiosis in Europe. Lancet 1995; 346: 782-783.
173. Horowitz HW, Raffalli J, Nadelman RB, Wu J, Wormser GP. Saddleback fever due to human granulocytic ehrlichiosis. Lancet 1998; 351: 650.
174. Moulding DA, Quayle JA, Hart CA, Edwards SW. Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 1998; 92: 2495-2502.
175. Savill JS, Wyllie AH, Hensen JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of ageing neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83: 865-875.
176. Stringer RE, Hart CA, Edwards SW. Sodium butyrate delays neutrophil apoptosis: role of protein biosynthesis in neutrophil survival. Br J Haematol 1996; 92: 169-175.
177. Edwards SW. Biochemistry and physiology of the neutrophil. Cambridge, Cambridge University Press. 1994.
178. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275: 199-205.
179. Calva JJ, Sifuentes-Osornio J, Cerón C. Antimicrobial resistance in fecal flora: longitudinal community-based surveillance of children from urban Mexico. Antimicrob Agents Chemother 1996; 40: 1699-1702.
180. Shears P, Hart CA, Broadhead RL, Coulter JBS. A note on antibiotic resistance in Escherichia coli isolated from children with diarrhoea in the Sudan. Ann Trop Paediatr 1987; 7: 38-41.
181. Wilson ME. Travel and the emergence of infectious diseases. Emerg Infect Dis 1995; 1: 39-46.
182. M'Zali FH, Heritage J, Gascoyne-Binzi DM, Denton M, Todd NJ, Hawkey PM. Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated AmpC-type β-lactamase exposed during an outbreak of SHV-5 extended-spectrum β-lactamase in a Leeds Hospital. J Antimicrob Chemother 1997; 40: 823-831.
183. Gascoyne-Binzi DM, Hawkey PM, Heritage J. The distribution of variants of the Tet M determinant in tetracycline-resistant Neisseria gonorrhoeae. J Antimicrob Chemother 1994; 33: 1011-1016.
184. Hall RM. Mobile gene cassettes and integrons: moving antibiotic resistance genes in Gram-negative bacteria. In: Antibiotic resistance: origins, evolution, selection and spread. Ciba Foundation Symposium. John Wiley, Chichester. 1997: 192-205.
185. Frost JA, Willshaw GA, Barclay EA, Rowe B, Lemmens P, Vandepitte J. Plasmid characterization of drug-resistant Shigella dysenteriae 1 from an epidemic in Central Africa. J Hyg 1985; 94: 163-172.
186. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496-514.
187. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the world-wide situation and the WHO/IUALTD Global Surveillance Project. Clin Infect Dis 1997; 24 Suppl 1: S121-S130.
188. Dowse LJ, Prigent BM. Epidemiology of beta-lactamases in Africa: correlation with resistance to beta-lactam antibiotics. Clin Ther 1991; 13: 243-253.
189. Ling JM, Lam AW, Ching AF. Prevalence of ampicillin-resistant Haemophilus influenzae community-acquired infections in Hong Kong. J Antimicrob Chemother 1993; 32: 346-347.
190. James PA, Hossain FK, Lewis DA, White DG. β-lactam susceptibility of Haemophilus influenzae strains showing reduced susceptibility to cefuroxime. J Antimicrob Chemother 1995; 32: 239-246.
191. Clairoux N, Picard M, Brochu A et al. Molecular basis of the non-β-lactamase-mediated resistance to β-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. Antimicrob Agents Chemother 1992; 36: 1504-1513.
192. Klugman KP, Koornhof HJ. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986. J Infect Dis 1988; 158: 956-964.
193. Courvalin P, Carlier C. Transposable multiple antibiotic resistance in Streptococcus pneumoniae. Mol Gen Genet 1986; 205: 291-297.
194. Dowson CG, Hutchinson A, Brannigan JA et al. Horizontal transfer of penicillin binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci USA 1989; 86: 8842-8846.
195. Reichmann P, König A, Liñares J et al. A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. J Infect Dis 1997; 176: 1001-1012.
196. Munoz R, Coffey TJ, Daniels M et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302-306.
197. Koh TH, Lin RV. Increasing antimicrobial resistance in clinical isolates of Streptococcus pneumoniae. Ann Acad Med Singapore 1997; 26: 604-608.
198. Botha P. Penicillin-resistant Neisseria meningitidis in Southern Africa. Lancet 1988; 1: 54.
199. International Conference for Antimicrobial Agents and Chemotherapy 1997. Chloramphenicol resistant Neisseria meningitidis.
200. Lind I. Antimicrobial resistance in Neisseria gonorrhoeue. Clin Infect Dis 1997; 24 Suppl 1: S93-S97.
201. Gascoyne-Binzi DM, Heritage J, Hawkey PM, Sprott MS. Characterisation of a tet(M)-carrying plasmid from Neisseria meningitidis. J Antimicrob Chemother 1994; 34: 1015-1023.
202. Pitout JDD, Thomson KS, Hanson ND, Ehrhardt AF, Moland ES, Sanders CC. β-lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob Agents Chemother 1998; 42: 1350-1354.
203. Lulitanond A, Kaewkas W, Kitcharoen K. Extended spectrum β-lactamases (ESBs) from Gram negative bacilli isolated from Srinagarind Hospital, Thailand. J Clin Microbiol Infect 1997; 3 Suppl 2: 300.
204. Shears P. A review of bacterial resistance to antimicrobial agents in tropical countries. Ann Trop Paediatr 1993; 13: 219-226.
205. Kariuki S, Gilks C, Corkhill J et al. Multi-drag resistant non-typhi salmonellae in Kenya. J Antimicrob Chemother 1996; 38: 425-434.
206. Riley LW, Ceballos BSO, Trabulzi LR, Fernandes de Toledo MR, Blake PA. The significance of hospitals as reservoirs for endemic multiresistant Salmonella typhimurium causing infection in urban Brazilian children. J Infect Dis 1984; 150: 236-241.
207. Kuschner RA, Trota AF, Thomas RJ et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21: 536-541.
208. Brown JC, Shanahan PMA, Jesudason MV, Thomson CJ, Amyes SGB. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996; 37: 891-900.
209. O'Brien TF. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis 1997; 24 Suppl 1: S2-S8.
210. Pang T, Levine MM, Ivanoff B, Wain J, Finlay BB. Typhoid fever - important issues still remain. Trends Microbiol 1998; 6: 131-133.
211. Mirza SH, Beeching NJ, Hart CA. The prevalence and clinical features of multi-drug resistant Salmonella typhi infections in Baluchistan, Pakistan. Ann Trop Med Parasitol 1995; 89: 515-519.
212. Hoa NTT, Diep TS, Wain J et al. Community-acquired septicaemia in southern Vietnam; the importance of multidrug-resistant Salmonella tvphi. Trans R Soc Trop Med Hyg 1998; 92: 503-508.
213. Colquhoun J, Weetch RS. Resistance to chloramphenicol developing during treatment of typhoid fever. Lancet 1950; 2: 621-623.
214. Anderson ES, Smith HR. Chloramphenicol resistance in the typhoid bacillus. BMJ 1972; 3: 329-331.
215. Coovadia YM, Van den Ende J. Chloramphenicol-resistant Salmonella typhi in Durban, South Africa. Trop Geogr Med 1987; 39: 64-66.
216. Olarte J, Galindo E. Salmonella typhi resistant to chloramphenicol, ampicillin, and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in Mexico. Antimicrob Agents Chemother 1973; 4: 597-601.
217. Taylor DE, Chumpitaz JC, Goldstein F. Variability of IncH II plasmids from Salmonella typhi with special reference to Peruvian plasmids encoding resistance to trimethoprim and other antibiotics. Antimicrob Agents Chemother 1985; 28: 452-455.
218. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr Infect Dis J 1994; 13: 134-140.
219. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol 1996; 44: 317-319.
220. Rowe B, Ward L, Threlfall EJ. Multi-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 1997; 24 Suppl 1: S106-S109.
221. Jesudason MV, John R, John TJ. The concurrent prevalence of chloramphenicol-sensitive and multidrug-resistant Salmonella typhi in Vellore, S. India. Epidemiol Infect 1996; 116: 225-227.
222. Karamat KA, Butt T, Hannan A et al. Problem of multidrug-resistant typhoid fever in Rawalpindi/Islamabad area. Pak Armed Forces Med J 1996; 46: 48-54.
223. Saha SK, Saha S, Ruhulamin M, Hanif M, Islam M. Decreasing trend of multiresistant Salmonella typhi in Bangladesh. J Antimicrob Chemother 1997; 39: 554-556.
224. Hampton MD, Ward LR, Rowe B, Threlfall EJ. Molecular fingerprinting of multidrug-resistant Salmonella enterica serotype Typhi. Emerg Infect Dis 1998; 4: 317-320.
225. Hermans PWM, Saha SK, van Leeuwen WJ, Verbrugh HA, van Belkum A, Goessens WHF. Molecular typing of Salmonella typhi strains from Dhaka (Bangladesh) and development of DNA probes identifying plasmid-encoded multidrug-resistant isolates. J Clin Microbiol 1996; 34: 1373-1379.
226. Mirza SH. Genetic analysis of multi-drug resistant Salmonella typhi from Pakistan and comparison with similar strains from other parts of Southeast Asia. University of Liverpool, MD thesis, 1997.
227. Fica AE, Prat-Miranda S, Fernandez-Ricci A, D'Ottone K, Cabello FC. Epidemic typhoid in Chile: analysis by molecular and conventional methods of Salmonella typhi strain diversity in epidemic (1977 and 1981) and nonepidemic (1990) years. J Clin Microbiol 1996; 34: 1701-1707.
228. Shanahan PMA, Jesudason MV, Thomson CJ, Amyes SGB. Molecular analysis of and identification of antibiotic resistance genes in clinical isolates of Salmonella typhi from India. J Clin Microbiol 1998; 36: 1595-1600.
229. Thong KL, Nair S, Chaudhry R et al. Molecular analysis of Salmonella paratyphi A from an outbreak in New Delhi, India. Emerg Infect Dis 1998; 4: 507-508.
230. Karamat KA, Mirza SH, Beeching NJ. Emergence of multiresistant Salmonella paratyphi A in Pakistan (abstract). J Infect 1998; 36: A9.
231. Parry CM, Beeching NJ. Epidemiology, diagnosis and treatment of enteric fever. Curr Opin Infect Dis 1998; 11: 583-590.
232. Brown JC, Shanahan PMA, Jesudason MV, Thomson CJ, Amyes SGB. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996; 37: 891-900.
233. Wain J, Hoa NTT, Chinh NT et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25: 1404-1410.
234. Jesudason MV, Malathy B, John TJ. Trend of increasing levels of minimum inhibitory concentration of ciprofloxacin to Salmonella typhi. Indian J Med Res 1996; 103: 247-249.
235. Parry C, Wain J, Chinh NT, Vinh H, Farrar JJ. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998; 351: 1289.
236. Chinh HT, Solomon T, Thong MX et al. Short courses of ofloxacin for the treatment of enteric fever. Trans R Soc Trop Med Hyg 1996; 91: 347-349.
237. Murdoch DA, Banatvala NA, Bone A, Shoismatulloev BI, Ward LR, Threlfall EJ. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 1998; 351: 339.
238. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 1999; 353: 1590-1591.
239. Gotuzzo E, Echevarrìa J, Carrillo C et al. Randomized comparison of aztreonam and chloramphenicol in treatment of typhoid fever. Antimicrob Agents Chemother 1994; 38: 558-562.
240. Bhutta ZA. Therapeutic aspects of typhoidal salmonellosis in childhood: the Karachi experience. Ann Trop Paediatr 1996; 16: 299-306.
241. Wain J, Diep TS, Ho VA et al. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol 1998; 36: 1683-1687.
242. White NJ, Parry CM. The treatment of typhoid fever. Curr Opin Infect Dis 1996; 9: 298-302.
243. Saha SK, Talukder SY, Islam M, Sana S. A highly ceftriaxone-resistant Salmonella typhi in Bangladesh. Pediatr Infect Dis J 1999; 18: 387.
244. Sethuraman S, Mahamood M, Kareem S. Furazolidone in multi-resistant childhood typhoid fever. Ann Trop Paediatr 1994; 14: 321-324.
245. Tribble D, Girgis N, Habib N, Butler T. Efficacy of azithromycin for typhoid fever. Clin Infect Dis 1995; 21: 1046-1046.